The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...

COVID-19 RNA may induce monocytes to develop cancer-fighting properties, potentially shrinking tumors in certain metastatic cancers. Patients resistant to prior immunotherapy showed the most benefit ...

The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December ...

Federal investment in RNA vaccine research has supported nearly three decades of scientific work spanning infectious diseases, cancer, and vaccine development, but recent and proposed funding cuts ...

Co-infection of influenza virus and SARS-CoV-2 can lead to more severe disease than infection of either alone.

Scientists have discovered a surprising silver lining of COVID-19 infection. A new study by researchers at Northwestern Medicine Canning Thoracic Institute, published in the Journal of Clinical ...

The COVID-19 virus may have the surprising ability to shrink some tumors, paving the way for new cancer treatments, a new study has found. The research, conducted at the Northwestern Medicine Canning ...

In patients with AF and COVID-19 who receive DOAC, 30-day mortality risk is similar for nirmatrelvir/ritonavir and RdRp inhibitors.

COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 that clinical trials will be required to approve annual COVID-19 ...

Explore how Moderna makes money through its mRNA vaccines, government contracts, and partnerships, and how products like its COVID-19 vaccine drive revenue.